Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
May 04, 2021 14:52 ET | Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 04, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
Nurix.png
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
April 13, 2021 16:01 ET | Nurix Therapeutics, Inc.
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after...
Nurix.png
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 07:00 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
arvinas logo.jpg
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05, 2021 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix.png
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
March 16, 2021 09:31 ET | Nurix Therapeutics, Inc.
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8...
22157.jpg
4 Report Package: "Drug the Undruggable" Technologies Bundle - Four Full Reports for the Price of Two
March 12, 2021 04:13 ET | Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Report Package: "Drug the Undruggable" Technologies" report has been added to ResearchAndMarkets.com's offering. This report package includes four...
arvinas logo.jpg
Arvinas to Participate in Upcoming Virtual Investor Conferences
March 10, 2021 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix.png
Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
March 09, 2021 07:30 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur...
Nurix.png
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
March 02, 2021 16:15 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...